Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Silo Pharma, Inc.

< Previous 1 2 3 Next >
Silo Pharma Selects Alphaledger’s T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company’s Commitment to Multi-Chain Growth
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma’s Alzheimer’s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers HOTH SILO
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Closing of $2 Million Public Offering
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Pricing of $2 Million Public Offering
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.